Two NIDDK programs, one focused on Type 1 Diabetes (see NIH grant here) and one focused on Obesity (see NIH grant here) funded three different groups with the goal of developing and disseminating targeted mass spectrometry assays for the diagnosis and monitoring of Type 1 Diabetes and Obesity.  While the funding sources are separate, we felt there were obvious synergies in these efforts and formed TaMADOR with the goal of leveraging each other's capabilities and strengths.

Part of the project? Click HERE for internal resources (agendas, meeting logs, etc).

Type 1 Diabetes Assays



Quantifying Proteins in Plasma to Democratize Personalized Medicine for Patients with Type 1 Diabetes



Obesity Assays


Design and Validation of Easy-to-Adopt Mass Spectrometry Assays of Importance to Obesity



Multiplex Mass Spectrometric Protein Assays for Precise Monitoring of the Pathophysiology of Obesity


Announcing TaMADOR: A Collaborative Working Group for Targeted Mass Spectrometry Assays 2020-05-08

Two NIDDK programs, one focused on Type 1 Diabetes (https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-17-019.html) and one focused on Obesity (https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-19-001.html) are working together to develop and share quantitative protein assays. Andy Hoofnagle's lab at the University of Washington is working on Type 1 Diabetes. Jenny Van Eyk's and Wei-Jun Qian's labs at Cedars-Sinai and PNNL respectively are working on Obesity. To leverage each other's capabilities and strengths we have formed a working group that we call TaMADOR (Targeted Mass Spectrometry Assays for Diabetes and Obesity Research).